|
FDA approves pilot cancer study by WVU
MORGANTOWN, W.Va. (AP) -- A pilot study at West Virginia University aimed at helping cancer patients who develop hand-foot syndrome has been approved by the U.S. Food and Drug Administration.
Researchers will test an ointment developed to prevent the syndrome, which is pain, numbness, tingling, reddening or swelling in the hands or feet.
The university said Friday that more than half the patients who receive the chemotherapy drug Capecitabine, marketed as Xeloda, develop hand-foot syndrome.
WVU worked with Adherex Technologies Inc., a biopharmaceutical research company, in preclinical studies of the ointment. University researchers developed the ointment from a drug that Adherex has been developing for other uses.
AP-ES-01-30-09 1341EST
|